ReviewProtein & cell2021
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Review in Protein & cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,475 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,475 citing papers in PubMed, 2,267 citations in OpenAlex.
- Disulfidptosis-based cancer therapy: Opportunity and challenge.Genes & diseases · 2027Review
- Rewiring redox defense: Nrf2-driven antioxidant signaling as a gateway to programmed cell death activation in colorectal cancer.Genes & diseases · 2027Review
- Molecular mechanism of Yishen Qingzhuo oral liquid in treating chronic renal failureRenal failure · 2026Article
- FTO-mediated mRNA biology · 2026Article
- Single-cell transcriptomics identifies PRDX1 and GPX4 as potential ferroptosis regulators and tumor microenvironment--related molecules in hepatocellular carcinoma.Oncology letters · 2026Article
- Breaking the cycle of fibrosis: Ferroptosis as a therapeutic target (Review).International journal of molecular medicine · 2026Review
- Exploring Ferroptosis: A Key Mechanism in Respiratory System Diseases and its Therapeutic Potential.Applied biochemistry and biotechnology · 2026Review
- Metabolic vulnerabilities in multiple myeloma: targeting iron and amino acid metabolism to induce ferroptosis.Apoptosis : an international journal on programmed cell death · 2026Article
- TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming.Cancer gene therapy · 2026Article
- Intranasal Curcumin and N-Acetyl l-Cysteine (NAC) Attenuates Dibutyl Phthalate (DBP)-Aggravated Airway Inflammation by Targeting Ferroptosis via Nrf-2/GPx4-SLC7A11.Environmental toxicology · 2026Article
- Ferroptosis in cancer: molecular mechanisms, biological roles, and therapeutic significance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- KIAA1429 knockdown alleviates osteosarcoma progression by destabilizing SLC7A11 mRNA via m6A methylation to promote ferroptosis.International journal of oncology · 2026Article
- Peroxiredoxin 4 Involved in Spermatogenesis by Affecting Oxidative Stress and Ferroptosis.Andrology · 2026Article
- Effects of Isorhapontigenin on Cell Viability, Colony-Forming Efficiency, and Ferroptosis via Methyltransferase-Like 14-Mediated mMolecular carcinogenesis · 2026Article
- SLC7A11-mediated disulfidptosis underlies the pathogenesis of proliferative diabetic retinopathy.Eye and vision (London, England) · 2026Article
- The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Ferroptosis in kidney disease.Nature reviews. Nephrology · 2026Review
- Integrating proteomics and metabolomics to reveal MAT2A for metabolic reprogramming in non-small cell lung cancer cells.iScience · 2026Article
- Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.Molecular therapy. Oncology · 2026Article
1,415 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.